4 Natural Ways to Ease Muscle Soreness After a Workout
After a great work out you may find yourself rewarded with sore muscles. Keep in mind that your muscles are just protein fibers that sustain intended damage during training. The goal should be to bring down the inflammation this process has caused. Instead of letting the cramps and soreness delay, next workout try a few natural remedies to keep your muscles strong and healthy.
Magnesium Supplements
Magnesium should be the go-to post-workout solution. When the body doesn’t have enough magnesium, the calcium then builds up causing cramps and spasms. Magnesium can be taken as a supplement or eat magnesium-rich foods post-workout like almonds, spinach, and cocoa. Epsom salt is a great place to start the healing journey, a warm bath with a cup of Epsom salt will help the muscles gather the magnesium out of the salty water. Be sure to check with your doctor if you take prescription medications before supplementing with magnesium.
Apple Cider Vinegar Drinks
Apple cider vinegar is both anti-inflammatory and alkalizing. Just what sore muscles need something to help reduce the inflammation. A teaspoon is all that is needed to start the muscle recovery process, it can be added to a cup of water if needed. It is also effective if applied topically.
CBD Cream
Sometimes muscle recovery needs a helping hand. A great solution is a 2000mg CBD joint pain cream. All you have to do is massage the affected area with the CBD cream and in about ten minutes the soreness will disappear. The skin absorbs the CBD, it is a powerful medicine (no prescription is needed). However, the CBD does not enter the bloodstream. It is more effective than the old sports menthols rubs that most folks are familiar with.
Turmeric Supplements
Internal support of reducing inflammation can be supplemented with turmeric. A 500mg capsule is all you need to help the body reduce inflammation after a workout. Turmeric is the ingredient in curry that gives it that yellow color and distinct flavor. It is not that exotic, turmeric capsules are readily available at drug stores and grocery stores. There are no side effects and it won’t put a taste in your mouth.
After a workout, there is no need to suffer from the pain and cramps of sore muscles. The four ingredients; magnesium, apple cider vinegar, CBD cream, and turmeric when used together treat muscles inside and outside. Natural remedies are safe to use. Together they provide a speedy recovery and no interruption in the workout schedule.
Roche Diabetes Care Canada collaborates with Ellerca Health to launch Accu-Chek® + 360Care™ for diabetes
Accu-Chek® + 360Care™ offers patients living with Type 1 and Type 2 diabetes innovative personalised solutions, empowering patients to actively monitor their glucose with real-time professional support, coaching using technology and human intervention
The Accu-Chek® Guide blood glucose meter along with "just in time" customized home testing strip delivery and Ellerca's 360Care™ app and health coaches help patients manage their health and worry less about their diabetes
Accu-Chek® + 360Care is an exclusive offer for Medavie Blue Cross plan members
LAVAL, QC, May 17, 2021 /CNW Telbec/ - Roche Diabetes Care Canada announces a collaboration with Ellerca Health, a Toronto-based company dedicated to improving patient care through innovation and technology. The partnership will include the launch of Accu-Chek® + 360Care™, combining Roche's Accu-Chek® Guide blood glucose meter, customized home delivery of testing strips and Ellerca's self-management digital program, 360Care™, which empowers patients to be in control of their own treatment schedule with access to a team of health coaches.
"At Roche Diabetes Care, we are dedicated to offering integrated, personalised diabetes management to Canadians living with diabetes," said Jade Dagher, Head of Sub-Region Canada, Australia and New-Zealand at Roche Diabetes Care. "This valuable partnership with Ellerca Health aims to further our mission to shape the future of diabetes management and help people living with diabetes take better control of diabetes and improve their disease outcome."
The Roche and Ellerca collaboration provides patients with a fully personalised and integrated solution that makes managing treatment easy and efficient. The offer consists of the Accu-Chek® Guide blood glucose meter, access to testing strips – which are sent directly to patients' homes and health coaching from a diabetes nurse educator, social worker, psychologist and/or nutritionist.
"We know that people living with diabetes and other chronic illnesses are looking for help and support throughout their health journey and we are proud to do our part to eliminate any added stress," said Daniel Yeboah, Founder + General Manager of Ellerca Health. "Through 360Care™, our virtual diabetes clinic and the help of partners like Roche we can help deliver life-changing solutions that empower patients to take back control of their daily lives."
Accu-Chek® + 360Care™ will be available to Medavie Blue Cross plan members as part of their Diabetes Care Program.
"This collaboration is a great example of companies coming together to create health solutions," said Marc Avaria, Vice President, Product and Disability Management at Medavie Blue Cross. "We are pleased to offer a robust Diabetes Care Program to plan members through our Managing Chronic Disease benefit. We will continue to focus on ways to enable better, more convenient access to education and care to help those with diabetes and other chronic conditions."
About Roche Diabetes Care Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 5,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.
Being a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes®, Accu-Chek® and mySugr®, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualising relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments. For better outcomes and true relief.
Since 2017, mySugr®, one of the most popular diabetes management apps, is part of Roche Diabetes Care.
About Ellerca Health Based in Toronto, Canada, Ellerca Health, is a digital health organization that uses the integration of mobile technology, real human interaction, artificial intelligence, and proven behavioral science to revolutionize the personal experience and health outcomes of people living with chronic disease. Ellerca Health's approach delivers continuous fully integrated virtual care and support, raising the bar in the digital therapeutics market.
Shifting the healthcare paradigm to engage and empower consumers, Ellerca Health is transforming chronic disease management, patient outcomes, and healthcare costs with its 360Care™ platform.
Driving 360Care™ is the core philosophy that people with chronic health needs, when provided with true care and companionship, quickly make the incremental behavioral changes needed to stop the progression of their conditions.
About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R+D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Madison Systems Inc. - Stanmac Broadband Inc. Press Release
TORONTO, May 17, 2021 /CNW/ - Madison Systems Inc. (MADI-OTC NASDAQ) and Stanmac Broadband Inc. (SBI) update our future role in the delivery of our proprietary and patented broadband technology (6 to 8 years ahead of the industry) in partnership with an associate company, Infinity Internet Solutions. The number of subscribers on the East Prairie project has been increasing steadily, lives have changed completely, they are ecstatic and the ISED (Innovation, Science and Economic Development) of Canada is approving additional licenses to further expand our reach to communities, currently lacking access to high-speed broadband. Madison Systems Inc./Stanmac Broadband Inc new patented product development.
During the Covid-19 pandemic, we have seen an unparalleled reliance on high-speed internet. Students (for schooling), people (working from home), every business has had to adapt and join the online marketplace, it's the way of the future growth of businesses. Unfortunately, millions of people in Canada and the USA do not have access to this basic essential service. In 2017, Canadian census reported that 37 percent of rural households and 24 percent of Indigenous households in Canada lacked high-speed broadband access. In the USA, approximately 30 million Americans lack high-speed broadband. Demand is extraordinary and through strategic partnerships, numerous spectrum licenses and unparalleled patented technology, Madi/SBI is positioned to supply affordable, reliable broadband and bridge the digital divide.
Our patented Connect Gen systems deliver broadband through the UHF spectrum providing internet, TV, telephone, and security without interruption or interference. Each Connect Gen system provides high-speed broadband with speeds of 100 to 200Mbps and supplies subscribers in a radius up to 60km from our tower without line-of-sight. Connect Gen systems are engineered, tested and field proven utilizing DOCSIS 3 and Channel Bonding to provide unrivaled capabilities, reaching rural/remote communities (of 20,000 plus homes & businesses).
Madi/SBI has an aggressive expansion plan for Canada/USA for 2021 and 2022. Our goal is to install up to 20 systems by the end of the year in rural and remote communities in need; including Indigenous communities, small towns and remote summer and winter homes. Rapid growth and implementation of our Connect Gen systems is our goal, and with licenses allowing us to utilize existing tower infrastructure, we are positioned to achieve these goals.
The Ontario and Federal Governments has recently released their 2021 budget which included up to $6 billion in rural internet infrastructure funding. Madi/SBI and Infinity Internet Solutions plan on expanding through it's ability to supply high speed broadband service across northern Canada allowing remote Canadians to access reliable internet. While the big telecom companies continue to under-serve rural and remote areas across Canada and Northern US states, Madi/SBI utilizing the new patented high-speed broadband technology are dedicated to connecting these communities with affordable and dependable broadband, encouraging cultural sustainability and essential community growth.
Future growth into the US market will be pursued as part of Madi/SBI mandate. With nearly 30 million Americans without access and a $100 billion pledge by the US Government to expand access to all Americans over the next 8 years, the opportunity for expansion is endless, and Madi/SBI will pursue all opportunities.
Don McNally President/CEO,
Please catch up with us and read our first two press releases; Oct 2nd, 2018 and Apr 13th, 2021
This press release may include forward-looking information within the meaning of OTC Markets Pink Guidelines, concerning the business and trading in the common stock of Madison Systems Inc. (MADI-OTC NASDAQ) such information is based on assumptions made by the company's management. Although the company believes these assumptions are reasonable, undue reliance should not be placed on the forward-looking information because the company can give no assurance that they will prove correct. These forward-looking statements are made as of the date of the press release and the company disclaims any obligation to update publicly any forward-looking information, other than required by applicable securities law.
The OTC Markets has not reviewed, approved, or disapproved the content of this press release.
SOURCE Madison Systems Inc.
Skylight Health Obtains Conditional Approval to List on NASDAQ Under the Symbol “SLHG”
TORONTO, May 13, 2021 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, today announced that the Company has received conditional approval from The Nasdaq Stock Market LLC ( “Nasdaq”) to list its issued and outstanding common shares on Nasdaq. Final approval of the listing is subject to the Company fulfilling any remaining conditions as required by Nasdaq. The Company expects to satisfy all of the requirements and will issue a statement once a trading date has been confirmed by Nasdaq. The Company’s common stock will continue to trade in Canada on the TSX Venture Exchange under its current symbol SHG; and until the NASDAQ listing, in the U.S. on the OTCQX under its current symbol, SHGFF.
“The anticipated listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly-traded company,” said Prad Sekar, CEO and Co-Founder of Skylight Health. “We believe this anticipated listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value. I would like to thank our employees, management, directors and our many collaborators for their hard work in obtaining conditional approval for Skylight Health to list on Nasdaq, an important step that will help facilitate our mission to provide primary services to Americans across the country.”
The Company also announces a change in auditor from Grant Thornton LLP (“Former Auditor”) to PricewaterhouseCoopers LLP (“Successor Auditor”) effective May 4, 2021. In accordance with NI 51-102, the notice of change of auditor, together with the required letters from the Former Auditor and the Successor Auditor, have been reviewed by the board of directors of the Company and filed on SEDAR.
About Skylight Health Group
Skylight Health Group (TSXV:SHG; OTCQX:SHGFF) is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state health network that comprises of physical multi-disciplinary medical clinics providing a range of services from primary care, sub-specialty, allied health and laboratory/diagnostic testing. The Company owns and operates a proprietary electronic health record system that supports the delivery of care to patients via telemedicine and other remote monitoring system integrations.
The Company primarily operates a traditional insurable fee-for-service model contracting with Medicare, Medicaid and other Commercial Payors. The Company also offers a disruptive subscription-based telemedicine service for the un/under-insured population who have limited access to urgent care due to cost.
Currency Usage, Cautionary and Forward-Looking Statements
All currency contained in this Press Release represent Canadian Dollars unless otherwise stated.
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Skylight Health's filings with Canadian and United States securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.
Forward-looking statements may include, without limitation, statements regarding the Company’s anticipated uplist to NASDAQ.
Although Skylight Health has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: the ability of Skylight Health to execute on its business strategy, continued revenue growth in accordance with management’s expectations, operating expenses continuing in accordance with management expectations, dependence on obtaining regulatory approvals; Skylight Health being able to find, complete and effectively integrate target acquisitions; change in laws relating to health care regulation; reliance on management; requirements for additional financing; competition; hindering market growth or other factors that may not currently be known by the Company.
There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Skylight Health disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Skylight Health does not assume any liability for disclosure relating to any other company mentioned herein.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
OBI's Data Releases Promise to Accelerate Discovery in Brain Health
Clinical data from over 5500 participants are ready to be mined by researchers for insights into brain health and disease
TORONTO, May 13, 2021 /CNW/ - The Ontario Brain Institute (OBI) announced the release of its first clinical data sets to promote open science and accelerate research in brain health through Brain-CODE, OBI's neuroinformatics platform. OBI's approach to data sharing offers the research community an opportunity to take advantage of clean, curated data to better understand brain disorders and identify new treatment options that would otherwise take years of work and resources.
Gathering large, well-curated datasets is a highly specialized, resource intensive process, but it has a big pay-off. By providing these assets to the international research community OBI aims to let researchers get right to the work. Using these data, researchers can delve into some of the most pressing questions and challenges that will ultimately improve quality of life for people living with brain disorders.
Designated a Privacy by Design ambassador by the Information and Privacy Commissioner of Ontario, Brain-CODE's safe and secure platform will make it easier for researchers, clinicians, and industry partners to collaborate with national and international research community in speeding up discovery.
"Data sharing fosters scientific discoveries by enabling the aggregation of multiple, disparate datasets as well as opening the process of gaining insights from the data to scientists not involved in the initial data gathering. Such democratization of data and science will lead to more robust and trustworthy results and conclusions", says Dr. Jason Lerch, Director, Preclinical Imaging, Wellcome Centre for Integrative Neuroimaging, University of Oxford and POND Investigator.
The first sets of clinical data were collected for research studies led by OBI's neurodevelopmental disorders (like autism) program (POND) and the Post-Concussive Problems In Pediatrics (5P) study that involved researchers from OBI's concussion research program (CONNECT). This set includes clinical data from over 5500 participants and later this year four more datasets including depression and neurodegenerative diseases (like Alzheimer's) will follow.
Currently, Brain-CODE has data from more than 20,000 participants across its six research programs: epilepsy, cerebral palsy, neurodegenerative diseases, neurodevelopmental disorders, depression and concussion. Brain-CODE's existing open data sets have been downloaded over 100 times during this past year alone with requests received from several countries including China, USA, Germany, Mexico and Australia.
"Science today is increasingly interdisciplinary, and researchers benefit enormously from having access to data and reliable information from various scientific fields," said Dr. Mona Nemer, Canada's Chief Science Advisor. "I am pleased to see that OBI has taken the lead on enabling open and safe sharing of research using an approach that reflects the values of transparency, inclusiveness and collaboration."
"The Ontario government is committed to supporting and recognizing scientific advances and innovations in the healthcare sector by Ontario's businesses and organizations to better the treatment and care of Ontarians," said Ross Romano, Minister of Colleges and Universities. "By sharing their first clinical data sets with the research community to better understand brain disorders and find new treatment options for those living with brain disorders, OBI continues to put Ontario on the map for its research and innovation in the brain health and healthcare sectors. OBI continues to develop ground-breaking research and 'Ontario Made' innovations and technologies that advance new discoveries and innovations that better the health and wellbeing of those living with brain disorders in our province."
"Improving brain health is a lofty goal, but by bringing the entire community together, OBI aims to unite us all under one banner to serve those in need," says Dr. Mikkelsen, President & Scientific Director, OBI. "Through the collaborative efforts of Ontario's community, we are breaking down barriers, encouraging a 'Team Science' approach to health research and most importantly honouring the time invested by our participants by reusing and recycling their data to help the generations to come."
If you wish to learn more about Brain-CODE or access the data releases, click here.
About Ontario Brain Institute:
The Ontario Brain Institute is a not-for-profit organization that accelerates discovery and innovation, benefiting both patients and the economy. Our collaborative 'team science' approach promotes brain research, commercialization and care by connecting researchers, clinicians, industry, patients, and their advocates to improve the lives of those living with brain disorders. Welcome to Brain Central. Visit www.braininstitute.ca for more information. Follow us on Twitter (@OntarioBrain). Funding provided, in part by, the Government of Ontario.
About Brain-CODE:
Brain-CODE is OBI's state-of-the-art neuroinformatics platform where data streams from OBI's six research programs and from institutions across Canada. Brain-CODE which is designed to store, manage and facilitate the analysis of data. OBI's Brain-CODE is a "shared brain" for researchers in Ontario and beyond. Please visit www.braincode.ca
SOURCE Ontario Brain Institute
A Globally Accessible Therapy Is Found to Protect Against Lethal Inflammation
from COVID-19 in Animal Models
New York, NY – Mount Sinai researchers have found that a widely available and inexpensive drug targeting inflammatory genes has reduced morbidity and mortality in mice infected with SARS-CoV-2, the virus that causes COVID-19. In a study published in Cell, the team reported that the drug, topotecan (TPT), inhibited the expression of inflammatory genes in the lungs of mice as late as four days after infection, a finding with potential implications for treatment of humans.
“So far, in pre-clinical models of COVID-19, there are no therapies– either antiviral, antibody, or plasma – shown to improve SARS-CoV-2 infection outcomes when administered after more than one day post-infection,” says senior author Ivan Marazzi, PhD, Associate Professor in the Microbiology Department at the Icahn School of Medicine at Mount Sinai. “This is a huge problem because people who have severe COVID19 and get hospitalized, often do not present symptoms until many days after infection. We took a different approach, and sought to find a potential therapy that can be used during later stages of the disease. We found that topoisomerase 1 (TOP1) inhibitors given days after the infection can limit the expression of inflammatory genes in the lungs of infected animals to prevent an “hyper-inflammatory status” Moreover, says Dr. Marazzi, topotecan (TPT), an FDA-approved TOP1 inhibitor, as well as its derivatives, are inexpensive clinical-grade inhibitors available in most countries around the world for use as anti-cancer agents.
Although the pathophysiology of SARS-CoV-2 is not yet fully understood, scientists have observed that the virus triggers excess production of cytokines and chemokines – chemicals, which are secreted by cells of the immune system to help fight infection. An exaggerated immune system response, which characteristically occurs in the lungs of COVID-19 patients, can flood the infected area with white blood cells, resulting in inflammation, possible tissue damage, organ failure, and death. Reduction of the inflammatory state in such patients could therefore improve their clinical outcomes.
In a previous study published in Science in 2016, the same group at Mount Sinai found that inhibiting the activation of inflammatory genes could help prevent animal deaths from viral and bacterial infections, and suggested this could be a potent strategy against future pandemics. The current study – led by Mount Sinai along with partners from Singapore, Hong Kong, the U.K., the U.S., and other global sites -- expands on that earlier work to show how epigenetic therapy, which addresses the chemical modifications that influence gene expression, could be harnessed against severe cases of COVID-19.
The team’s research suggests that many other anti-inflammatory agents are less effective against COVID-19 because they target single inflammatory mediators, such as IL-6 or IL-1, or only specific gene expression programs. “The fact is, a multitude of inflammatory genes and signaling pathways are dysregulated during a SARS-CoV-2 infection,” explained lead author Jessica Sook Yuin Ho, PhD, a postdoctoral researcher at the Icahn School of Medicine. “We demonstrated that TOP1 inhibitors were able to broadly dampen inflammatory gene expression in animal models, regardless of the gene or activation pathway.”
The safety and efficacy of this treatment strategy in humans will soon be evaluated at clinical sites around the world, including India, where a trial recently began. The World Health Organization (WHO) is expected to play an important role in these studies.
“Findings from our work suggest that repurposing TOP1 inhibitors could be a valuable global strategy for treating severe cases of COVID-19,” emphasizes Dr. Marazzi. “Particularly attractive is the fact TPT is already FDA-approved and that its derivatives are inexpensive, with generic formulations existing throughout the world. This makes these drugs readily accessible and available for immediate use in both developed and developing countries across the world.”
About Dr. Ivan Marazzi
Dr. Marazzi is an Assistant Professor with Tenure in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai in NY, NY, USA. He has a broad background in virology, immunology, molecular biology and biochemistry, genetics and epigenetics. Over the course of his career, Dr. Marazzi has been active in several areas—including coding and non-coding RNA biology, genetics and epigenetics of the immune system, evolutionary biology and genomic of viruses. The major focus of Dr. Marazzi’s ongoing research is the investigation of unique and shared molecular pathways that control inflammatory responses established by infections and cancer initiation and progression, with a focus on how these processes can be targeted to ameliorate disease.
Dr. Marazzi’s transformative discoveries have resulted in many distinguished awards, including the Chan Zuckerberg Institute-Ben Barres Challenge in Neurodegeneration in 2018 . Dr. Marazzi’s research has been published by both the media and scientific journals and his work has resulted in multiple patents for novel treatment of infectious and inflammatory diseases.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services.
4 Tips for Doing Physical Therapy as a Senior
Whether you're recovering from an injury or trying to regain your old range of motion, physical therapy is an important part of many senior lifestyles. Follow these tips to make sure that you're getting the most out of whatever therapy routine you decide to follow.
Choose the Right Physical Therapist
One of the most important ways to make sure that you stick to aphysical therapy program is to choose a specialist that makes you feel comfortable. Look for a talented and professional team that knows how to treat your specific condition. Don't be afraid to ask for a tour or to try out a few paid sample sessions before you sign a long-term contract.
Attend All of Your Appointments
Physical therapy sessions are typically scheduled for two or three times a week. Although it can be tempting to skip the occasional appointment, this is an incredibly bad habit to get into. Do your best to make every single appointment, and understand that you probably can't afford to skip more than one meeting every month. Many physical therapists will be willing to reschedule for you if something comes up that forces you to miss your regularly scheduled session.
Do Your Home Exercises
No one likes to do homework, especially when they've been out of school for decades. However, the at-home exercises that your physical therapist prescribes for you are absolutely essential for your health and recovery. Pick a time of day to do your workout, and treat these moments with the same amount of respect as your scheduled appointments. If you're worried about your ability to keep up with your daily routine, ask a family member to work out alongside you. You might be surprised at how much easier it is to complete daily tasks when you have someone in your household to hold you accountable.
Celebrate Every Success
Physical therapy isn't always easy, and slow improvements can be difficult to notice. Try tracking your workouts and making note of how your capabilities increase over time.
Every time you hit a minor milestone, such as doubling your reps or achieving a new range of motion, find some way to celebrate yourself. Whether it's going out to lunch with your favorite family member or simply acknowledging your achievement, these minor moments of celebration will help keep you motivated as you complete your recovery journey.
Physical therapy isn't about reaching a set goal; it's about slowly improving your body's capabilities over time. No matter how small your steps may seem, it's important to keep progressing at a forward pace. Before you know it, you'll regain a serious amount of mobility and will be able to live a lifestyle that you thought was lost forever.
If you want to listen to the newest podcast im featured on:
The interview is now live on Big Idea Big Moves and is being listened to by people from around the world. It can be found on the following platforms.
New York, NY, May 13, 2021 —Do you miss hanging out with your friends? Want to see live sports or concerts? Done with Zoom? Then roll up your sleeves and get vaccinated, encourages top NYC plastic surgeon Dr. Richard Westreich.
He has joined the movement to help spread the truth about the efficacy and safety of the COVD-19 vaccines and to dispel misconceptions swirling on social media.
“If you’ve held off on getting a COVID-19 vaccine because you think it was created too quickly, this is definitely not the case,” Dr. Westreich says. “The vaccines have been more than three decades in the making. They were pulled off the shelf and used and began being developed for SARS-COVID-1 in 2003. This outbreak stopped and there was no need to continue. It was pulled off the shelf again in 2012 for the MERS outbreak; this was a very limited outbreak. Misinformation should not be a reason to not get vaccinated.”
He and his dedicated team have created fun and informative videos featuring familiar tunes with re-tooled lyrics to encourage more Americans to “crush COVID” by getting their vaccines.
The Centers for Disease Control and Prevention recently reported that 30 percent of the entire U.S. population is fully vaccinated and that more than 43 percent have received at least one dose. But medical experts agree that herd immunity is still a distant dream if more people can’t be persuaded to get the vaccine.
“Based on what we know, getting a COVID-19 vaccine also helps keep you from getting seriously ill even if you do get COVID-19 and will protect those around you,” Dr. Westreich adds. “My staff and I created these videos as a fun way to not only shed light on a serious situation, but also to spread very important awareness about the importance of getting the vaccine and to save lives.”
Dr. Richard Westreich graduated Magna Cum Laude with a B.A. in Biological Basis of Behavior, Neuroscience concentration in 1995 from the University of Pennsylvania. He completed his medical school training at the New York University School of Medicine in 1999 with an M.D. and Honors in Cell Biology Research. Dr. Westreich then did his post-graduate training in Facial Plastic Surgery and Otolaryngology at the prestigious Mt. Sinai Hospital in New York City.
He has been selected multiple times by Castle Connolly and New York magazine as one of the top doctors in facial plastic surgery. He is an assistant professor at SUNY Downstate Medical Center and is on staff at Lenox Hill and Mount Sinai Hospitals. He is a faculty member and teacher at a fellowship in Facial Plastic Surgery at Mount Sinai. His private practice is located on the Upper East Side of Manhattan, where he specializes in rhinoplasty, septoplasty, secondary and reconstructive rhinoplasty, facelifts, eyelid surgery and nonsurgical procedures.
WWC Conference to be largest virtual event for women in the cannabis and psychedelic industries
Toronto, ON, May 13, 2021 (GLOBE NEWSWIRE) -- Award-winning cannabis and marketing firm, Marigold PR, has announced the eagerly anticipated Womxn, Wellness and Cannabis Conference (WWC Conference) is poised to be the biggest ever. Taking place May 26 – 27, in celebration of the feminine cannabis and psychedelic experience, the largest free event of its kind unites women globally for two days of female-led panel discussions, Q&As and keynotes.
Hosted in association with Platinum Partner Lift & Co. Expo, North America’s largest cannabis industry conference and tradeshow, day one will be committed to cannabis programming with psychedelics slated for day two. “Lift & Co. Expo is honored to partner with WWC Conference to support women led organizations,” says Lacey Houston, Manager of Sales at Lift & Co. Expo. “This is going to be an impactful event and Lift & Co. Expo is excited to see the women leading the Cannabis and Psychedelics community come together to shape the future of the industry.”
With over 80 speakers representing four continents, WWC Conference provides an educational platform to learn from, and network with, international thought leaders in cannabis and psychedelics. As cannabis markets emerge globally and the buzz builds around psychedelics, creating inclusive spaces for women to connect and collaborate is essential.
For industry professionals, and those looking to break into the blossoming cannabis and psychedelics space, this year’s WWC Conference features a series of ticketed networking events. These provide exclusive opportunities to forge commercial relationships with business leaders, experts and influencers from across the burgeoning markets.
Cannasupplies’ Executive Director, Hilary Lieberman, says, “Creating a stage for thought provoking discussions that promote inclusion is vital to normalize cannabis consumption. Faced by ongoing travel restrictions, occasions that empower like minded professionals from across the world to build strategic alliances are of paramount importance. As the industry landscape continues to evolve, Cannasupplies is proud to support groundbreaking events that champion diversity and shape the sector’s future.”
